How Much Does a Reclast Infusion Cost?

Updated on August 23, 2026 | Written by Alec Pow
This article was researched using 14 sources. See our methodology and corrections policy.

A Reclast infusion can cost about $95 at one current freestanding infusion provider, while the drug alone can range from roughly $74 to $101 for discounted generic zoledronic acid to about $1,287 to $1,596 for brand Reclast. Current cash data lists brand Reclast from $1,286.58 in the current Reclast price guide and an FDA-approved generic from about $101.04 in current generic pricing.

The full appointment can cost more because the medication is only one part of the bill. A provider may separately charge for IV administration, the infusion suite, supplies, pre-infusion testing, and a clinician visit. Insurance can reduce the patient’s share sharply, while a hospital outpatient department can add facility cost sharing.

Reclast is zoledronic acid 5 mg given through an IV. For osteoporosis treatment it is normally given once yearly. For prevention of postmenopausal osteoporosis, the labeled schedule is once every two years.

Article Highlights

• Discounted generic zoledronic acid can bring the drug-only price to roughly $74 to $101 (at $30 per hour, earning that amount would take about 2.5 to 3.4 hours of work, before taxes).
• Brand Reclast cash pricing is about $1,287 to $1,596 for one 5 mg/100 mL container before administration.
• The infusion location can matter more than the vial price because hospital outpatient care may create separate facility cost sharing.
• The 2026 Medicare Part B deductible is $283, followed by the usual 20% patient share of Medicare-approved Part B services.
• Kidney function is checked before each dose, and Reclast is contraindicated when creatinine clearance is below 35 mL/min.
• The medication must be infused over at least 15 minutes.

How Much Does a Reclast Infusion Cost?

Cost item	Current benchmark	What the number covers
Generic zoledronic acid 5 mg/100 mL	About $74 to $101+ (about 2.5 to 3.4 hours of work at $30 per hour)	Drug-only cash or discount pricing
Brand Reclast 5 mg/100 mL	About $1,287 to $1,596	Drug-only cash benchmark
Independent infusion-provider example	$95.15 per visit	One provider’s posted Reclast price, not a national rate
2026 Medicare Part B deductible	$283	Annual deductible before Original Medicare begins paying applicable Part B costs
Original Medicare patient share after deductible	Usually 20%	Share of the Medicare-approved amount when standard Part B rules apply
Brand Prolia cash benchmark	About $1,895 per dose	Drug-only comparison for a medicine normally given twice yearly

SingleCare shows the size of the brand-generic gap from another current source. Its August 23, 2026 data lists average brand retail around $1,595.68 and a generic discount example as low as $73.74 for 5 mg/100 mL, while telling patients to ask whether the infusion site accepts the coupon in its current Reclast pricing. Against that coupon benchmark, the $1,286.58 brand cash benchmark is about 17.4 times higher because $1,286.58 ÷ $73.74 = 17.45.

A pharmacy coupon does not automatically become the price on an infusion-center bill. Many sites buy the drug themselves and bill it through the medical benefit. In that arrangement, the provider’s contracted drug amount and administration charge replace the pharmacy-counter transaction.

What You’re Actually Buying

Reclast is an intravenous bisphosphonate used for several forms of osteoporosis and for Paget’s disease of bone. A healthcare professional starts an IV, administers a ready-to-infuse zoledronic acid solution, monitors the patient during the visit, and follows the treatment plan set by the prescriber.

The once-yearly treatment schedule makes its billing different from weekly tablets or medicines given every six months. The visit also includes safety checks that are separate from the drug itself. Kidney function must be reviewed before dosing, hydration matters, and calcium status can affect whether treatment proceeds.

A patient may see several billing lines tied to one yearly treatment even when the medication bag is inexpensive. The useful financial comparison is the complete episode of care and the patient’s insurance liability, not only the pharmacy price of one container.

Under $100 or Much Higher

One freestanding provider, Sage Infusion, currently posts a $95.15 (about 3.2 hours of work at $30 per hour) Reclast price per visit and lists typical patient out-of-pocket amounts below $100 for commercial insurance, $0 for Medicare, and $18.30 for Medicare Advantage at its locations. Those are provider-specific figures rather than national averages, but they show how low a contracted visit price can be in a current Reclast infusion listing.

Hospital outpatient billing can look very different. Medicare says a patient may pay more for the same care in a hospital outpatient department than in a doctor’s office and may owe a hospital copayment for each service in addition to the clinician’s charge, according to Medicare’s outpatient hospital rules.

This is why a large hospital chargemaster number should not be presented as the national Reclast price. The useful figures are the insurer’s allowed amount and the patient’s final responsibility. An uninsured patient should request a written self-pay quote stating whether the drug, IV administration, supplies, facility charge, and required monitoring are included.

Medicare 

Original Medicare’s Part B deductible is $283 in 2026. After that deductible is met, beneficiaries usually pay 20% of the Medicare-approved amount for covered Part B services when standard assignment rules apply, according to Medicare’s 2026 cost schedule.

Take a hypothetical Medicare-approved Reclast encounter of $600. If the annual Part B deductible has already been met, the 20% patient share is $120 because $600 × 0.20 = $120.

If none of the deductible has been met, the patient first pays $283. That leaves $317 subject to the 20% share, or $63.40. The constructed patient total is $346.40: $283 + $63.40 = $346.40. Medigap, Medicare Advantage, Medicaid, employer coverage, or other insurance can change the result, so this example explains the arithmetic rather than predicting one person’s bill.

Pre-Infusion Tests, Supplements

The current prescribing information requires a serum creatinine test before each dose and calculation of creatinine clearance using actual body weight. Zoledronic acid is contraindicated when creatinine clearance is below 35 mL/min or when acute renal impairment is present, and the infusion must run for at least 15 minutes, according to the current Reclast prescribing information.

The same labeling calls for a routine oral examination before treatment begins. This is relevant because osteonecrosis of the jaw is a recognized bisphosphonate risk. A clinician may request dental assessment or treatment before infusion when the patient’s history raises concern.

For osteoporosis, the label recommends an average of at least 1,200 mg of calcium and 800 to 1,000 IU of vitamin D daily when dietary intake is inadequate. Bone Health and Osteoporosis Foundation guidance also describes yearly 5 mg treatment, every-two-year prevention dosing, kidney testing, and the oral examination in its zoledronic acid patient guidance.

Flu-like symptoms, fever, headache, and muscle or joint pain can occur after an infusion, especially after the first dose. An extra call, medication, lab test, or visit can create another charge if symptoms need medical attention.

There is also a hidden pre-treatment cost. A patient can pay for labs and clinical review and then have the infusion postponed because kidney function, hydration, calcium status, or another issue needs correction first. The testing still has medical value, but it remains part of the patient’s treatment-related spending.

Reclast vs. Prolia and Forteo

Current brand Prolia cash pricing is about $1,894.78 per 60 mg syringe, and the medicine is normally administered every six months, according to current Prolia cash pricing. Two doses at that benchmark equal $3,789.56 per year before administration.

Insurance can make that comparison look completely different. Amgen says Prolia may be covered through Medicare Part B or Part D depending on how it is supplied, while eligible commercially insured patients can use its support program to reduce out-of-pocket cost to as little as $0 per dose under the current Prolia payment terms. Amgen warns that stopping, skipping, or delaying Prolia can raise the risk of fractures, including spinal fractures, in its current patient guidance.

Forteo is a daily self-administered anabolic therapy rather than an annual infusion. Lilly’s current savings program lets eligible commercially insured patients pay as little as $4 per 28-day fill, with 2026 program limits, while Medicare, Medicaid, Medicare Advantage, Medigap, VA, TRICARE, and other government-funded beneficiaries are excluded under the current Forteo savings terms.

These therapies are not interchangeable products chosen by price alone. The prescribing decision depends on fracture risk, prior treatment, kidney function, dosing history, and the clinician’s plan.

Three Reclast Cost Scenarios

Low cash-provider scenario: A patient finds a freestanding clinic with a published Reclast visit price near $95. Before booking, the patient checks whether the quote includes the required laboratory work and prescriber review or whether those arrive on separate bills.

Original Medicare scenario: A medically covered encounter has a hypothetical $600 Medicare-approved amount. With the Part B deductible already satisfied, the constructed patient share is $120. With none of the deductible met, the same example produces $346.40 before supplemental coverage.

Brand cash scenario: A patient quoted brand-name Reclast can face a drug-only amount around $1,300 to $1,600 before the infusion site adds its own charges. Asking whether generic 5 mg/100 mL zoledronic acid is available can materially change the medication line.

Worked annual cost example

Suppose a self-pay clinic quotes a hypothetical $250 for generic zoledronic acid plus administration and the pre-infusion laboratory work costs another $80. The constructed treatment-day total is $330: $250 + $80 = $330. If a separate specialist visit costs $150, the episode becomes $480. These numbers are scenario math rather than quoted national rates. The calculation shows why the complete price needs every billed component rather than one pharmacy coupon.

Who This Cost Makes Sense For

Makes sense if:

• Your clinician selected zoledronic acid based on fracture risk, treatment history, and kidney function.
• You prefer a treatment given once yearly rather than frequent oral dosing.
• Your insurer or infusion center can provide the allowed amount and expected patient responsibility before the appointment.
• A generic zoledronic acid option is available at the selected site of care.

Does not make sense if:

• You are comparing only the retail vial price and ignoring administration and facility charges.
• Your kidney function or another contraindication makes Reclast unsuitable.
• You plan to switch from another osteoporosis medicine based only on price without a treatment-transition plan.
• You are delaying a medically scheduled dose solely to chase a deductible advantage without discussing timing with the prescriber.

What We Verified

• Checked the Endocrine Society’s osteoporosis treatment guidance, which recommends a fracture-risk review after three to five years of bisphosphonate therapy and says three years is an appropriate shorter review point for annual IV zoledronic acid.
• Confirmed that Medicare covers certain outpatient drugs administered through an IV under Part B and says patient cost depends on other insurance, provider charges, assignment, facility type, and location in its outpatient drug coverage rules.

Related Bone Health Costs

Osteoporosis care can create expenses outside the infusion itself. Monitoring may include a bone density scan, while fracture recovery can involve a bone growth stimulator or an Exogen bone healing system. Those services answer different medical needs and should not be folded into the annual Reclast price.

Answers to Common Questions

How much is Reclast without insurance?

Current cash benchmarks put generic zoledronic acid as low as roughly $74 to $101 for the drug alone, while brand Reclast can exceed $1,200. Administration, testing, and facility charges can be separate.

Does Medicare pay for Reclast?

Provider-administered outpatient drugs can be covered under Medicare Part B when coverage requirements are met. In 2026, the Part B deductible is $283, followed by the usual 20% share of the Medicare-approved amount under Original Medicare.

How long does a Reclast infusion take?

The medication must run for at least 15 minutes. The full appointment can last longer because of IV setup, basic monitoring, flushing, and observation.

What tests are needed before Reclast?

Serum creatinine and calculated creatinine clearance are required before each dose. A routine oral examination is also performed before treatment starts.

Can I switch from Prolia to Reclast to save money?

A transition can be appropriate for some patients, but the timing must be planned by the treating clinician. Do not stop, skip, or delay Prolia based on price alone because fracture risk can rise after interruption.